HeartMate 3植入同期三尖瓣手术的长期结局:ELEVATE注册研究
基于ELEVATE注册研究540例HM3患者中463例合并至少轻度三尖瓣反流者,比较同期行三尖瓣手术(70例,15.1%)与未行手术者的5年结局;匹配队列分析显示两组5年生存率无差异,但同期三尖瓣手术组右心衰竭风险更低,功能容量与右心功能可能获益。
要点
- HM3植入同期三尖瓣手术不改变5年生存率(69.0% vs 59.3%,P=.67)。
- 同期三尖瓣手术组右心衰竭风险更低(EPPY 0.038 vs 0.092,P=.03)。
- 匹配队列中两组5年6分钟步行距离与生活质量无显著差异。
核心结论
- ELEVATE注册研究中,HM3植入同期三尖瓣手术与5年生存率无差异,但可能对功能容量和右心功能有积极作用。
研究设计与样本
- ELEVATE注册研究纳入26个中心540例HM3患者,其中463例原发LVAD植入且合并至少轻度三尖瓣反流者纳入分析,同期三尖瓣手术70例(15.1%)。
- 比较总体人群(同期手术n=70 vs 未手术n=264)及匹配队列(每组n=67,主要分析队列)的5年结局。
主要发现
- 匹配队列中,同期手术组与未手术组基线年龄(57.9±10.8 vs 57.3±10.0,P=.728)、男性比例(92.5% vs 94.0%,P=1.000)、术前短期机械循环支持率(6.0% vs 9.0%,P=.744)、NYHA分级、生活质量评分及终末器官功能无差异。
- 术前同期手术组6分钟步行距离较短(58.0±109.0 m vs 105.3±154.0 m,P=.081)。
- 5年时,同期手术组与未手术组生存率(69.0% vs 59.3%,P=.67)、6分钟步行距离(311.1±129.5 m vs 295.6±137.7 m,P=.758)、生活质量评分及终末器官功能无差异。
- 同期手术组右心衰竭风险更低(EPPY 0.038 vs 0.092,P=.03)。
临床怎么用
- 对于HM3植入合并至少轻度三尖瓣反流的患者,同期三尖瓣手术不改善5年生存,但可能降低右心衰竭风险并有利于功能容量。
- 临床决策可综合考虑右心功能与功能状态,个体化选择是否同期行三尖瓣手术。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess whether tricuspid valve surgery (TVS) during HeartMate 3 (HM3) left ventricular assist device (LVAD) implantation affects long-term survival and outcomes. METHODS: The ELEVATE registry enrolled 540 HM3 patients across 26 centres; 463 undergoing primary LVAD implantation and at least mild tricuspid regurgitation (TR) formed this analysis. Concomitant TVS was performed in 70 (15.1%) patients. Five-year outcomes (survival, functional capacity, end-organ function, adverse events) were compared with those with similar severity of TR not receiving TVS in both overall population (with TVS n = 70 vs without TVS n = 264) and matched groups (each group n = 67, primary analysis cohort). RESULTS: In the matched cohort, baseline demographics of patients with or without TVS showed no differences in age (57.9 ± 10.8 vs 57.3 ± 10.0; P = .728), sex (male, 92.5% vs 94.0%; P = 1.000), preoperative short-term mechanical circulatory support rate (6.0% vs 9.0% P = .744), New York Heart Association (NYHA) class and quality of life (QoL) score, and end-organ function. Preoperatively, patients with TVS had shorter 6-minute walk distances (6MWD; 58.0 ± 109.0 m vs 105.3 ± 154.0 m; P = .081). At 5 years, patients with TVS showed no differences in survival (69.0% vs 59.3%, P = .67), 6MWD (311.1 ± 129.5 m vs 295.6 ± 137.7 m, P = .758), QoL score, or end-organ function while presented a lower risk of right heart failure (EPPY 0.038 vs 0.092, P = .03). CONCLUSIONS: In the ELEVATE registry, concomitant TVS during HM3 implantation was not associated with differences in 5-year survival; however, it may have a positive effect on functional capacity and right heart function. CLINICAL REGISTRATION NUMBER: NCT02497950.
引用
- Färber G, Zimpfer D, Garbade J, et al. Concomitant Tricuspid Valve Surgery During HeartMate 3 LVAD Implantation and Long-Term Outcomes: Insights From the ELEVATE Registry. Eur J Cardiothorac Surg. 2026. PMID: 41871602. doi:10.1093/ejcts/ezag106
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。